Your Health, We Care
Release date: 2024-08-05 15:18:00 Recommended: 99
Sotorasib, an oral inhibitor targeting the KRAS G12C mutation, is predominantly utilized in the treatment of non-small cell lung cancer (NSCLC). Clinical trials have demonstrated the efficacy of Sotorasib in significantly prolonging patients' progression-free survival and enhancing their quality of life.
During the administration of Sotorasib, patients must be particularly cautious of potential drug interactions to avoid any further jeopardy to their health.
As a CYP3A4 inducer, co-administration of Sotorasib with CYP3A4 substrates such as Simvastatin, Losartan, and Midazolam, may diminish the plasma concentrations of these substrates, impacting their effectiveness. Patients should refrain from combining Sotorasib with CYP3A4-sensitive substrates. If co-administration is necessary, dosage adjustments of these substrates should be made based on prescription information.
Sotorasib also acts as a P-gp inhibitor, and when used alongside P-gp substrates like Pazopanib, Everolimus, Digoxin, Dabigatran Etexilate, Rivaroxaban, and Apixaban, it can elevate the plasma concentrations of these substrates, potentially heightening the risk of adverse reactions. Patients should similarly avoid the concomitant administration of Sotorasib with P-gp substrates. If unavoidable, the dosage of P-gp substrates should be reduced according to prescription information.
Being a BCRP inhibitor, concurrent use of Sotorasib with BCRP substrates such as methotrexate, doxorubicin, and mitoxantrone can also elevate the plasma concentrations of these substrates, increasing the risk of related adverse reactions. Patients utilizing Sotorasib should closely monitor BCRP substrate-related adverse reactions and adjust the dosage as necessary.
Sotorasib is a prescription medication, and patients must strictly adhere to the physician's prescribed dosage and schedule, refraining from altering the medication dosage independently. Before commencing treatment, thorough communication with the physician to understand the administration, contraindications, and precautions of the drug is imperative.
Patients using Sotorasib should take note of the following precautions:
Patients must strictly adhere to the doctor's instructions and medication guidelines when using Sotorasib, refraining from altering the dosage or frequency of administration independently.
During the Sotorasib treatment period, patients should closely monitor any bodily changes, promptly informing the physician in case of adverse reactions such as diarrhea, musculoskeletal pain, nausea, fatigue, etc., to receive appropriate management recommendations.
[warm tips] Sotorasib is an effective targeted therapy drug, and patients should pay special attention to the aforementioned precautions when using it. It is crucial to follow the guidance of healthcare professionals, and in case of any queries or discomfort, seek immediate medical consultation.
